Market Place
Sourcing Support
GoodRx and Biogen Collaborate to Enhance Enrollment Experience for Providers
13 Oct 2022 //
BUSINESSWIRE
SMC approves diroximel fumarate as multiple sclerosis treatment
08 Feb 2022 //
PHARMAFILE
MHRA authorises Vumerity for multiple sclerosis patients
19 Nov 2021 //
PHARMATIMES
European Commission grants marketing authorisation for Vumerity
17 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
The European Commission Grants Marketing Authorization for VUMERITY®
16 Nov 2021 //
GLOBENEWSWIRE
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes
13 Oct 2021 //
GLOBENEWSWIRE
Euro Roundup: CHMP recommends drugs from Biogen & Roche, knocks back Pfizer
23 Sep 2021 //
RAPS
CHMP Recommends VUMERITY for Approval in European Union for Multiple Sclerosis
17 Sep 2021 //
GLOBENEWSWIRE
Biogen`s lagging Vumerity faces `critical` stretch ahead: CEO
23 Jul 2020 //
FIERCE PHARMA
Alkermes Receives $150M Biogen Milestone
12 Nov 2019 //
CONTRACT PHARMA
FDA approves Vumerity to treat relapsing forms of MS
01 Nov 2019 //
PHARMACEUTICAL-TECHNOLOGY
Alkermes +1.5% on tentative Vumerity approval
17 Oct 2019 //
SEEKINGALPHA
Biogen trumpets safety data for Tecfidera follow-up
30 May 2019 //
PMLIVE
Alkermes & Biogen USFDA Acceptance of Diroximel Fumarate NDA Multiple Sclerosis
25 Feb 2019 //
PR NEWSWIRE
Alkermes and Biogen announce new MS drug application for FDA
18 Dec 2018 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.